Mersana Therapeutics Inc’s recent filing unveils that its VP, Chief Accounting Officer Mandelia Ashish unloaded Company’s shares for reported $2061.0 on Jan 16 ’25. In the deal valued at $0.58 per share,3,554 shares were sold. As a result of this transaction, Mandelia Ashish now holds 57,519 shares worth roughly $20131.649999999998.
Then, Protopapas Anna sold 8,637 shares, generating $5,009 in total proceeds. Upon selling the shares at $0.58, the Director now owns 168,041 shares.
Before that, Lowinger Timothy B sold 8,048 shares. Mersana Therapeutics Inc shares valued at $4,668 were divested by the SVP, Chief Sci.&Tech. Officer at a price of $0.58 per share. As a result of the transaction, Lowinger Timothy B now holds 257,673 shares, worth roughly $90185.54999999999.
William Blair initiated its Mersana Therapeutics Inc [MRSN] rating to an Outperform in a research note published recently. JP Morgan also remained covering MRSN and has increased its forecast on March 19, 2024 with a “Neutral” recommendation from previously “an Underweight” rating. Wedbush revised its rating on February 29, 2024. It rated MRSN as “an Outperform” which previously was an “a Neutral”.
Price Performance Review of MRSN
On Tuesday, Mersana Therapeutics Inc [NASDAQ:MRSN] saw its stock fall -6.98% to $0.35. Over the last five days, the stock has lost -13.17%. Mersana Therapeutics Inc shares have fallen nearly -75.29% since the year began. Nevertheless, the stocks have fallen -84.08% over the past one year. While a 52-week high of $2.83 was reached on 01/02/25, a 52-week low of $0.26 was recorded on 04/10/25.
Levels Of Support And Resistance For MRSN Stock
The 24-hour chart illustrates a support level at 0.3400, which if violated will result in even more drops to 0.3300. On the upside, there is a resistance level at 0.3700. A further resistance level may holdings at 0.3900.
